Matti Davis

1.2k total citations · 1 hit paper
8 papers, 949 citations indexed

About

Matti Davis is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Matti Davis has authored 8 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Matti Davis's work include Ubiquitin and proteasome pathways (3 papers), Hedgehog Signaling Pathway Studies (2 papers) and Epigenetics and DNA Methylation (2 papers). Matti Davis is often cited by papers focused on Ubiquitin and proteasome pathways (3 papers), Hedgehog Signaling Pathway Studies (2 papers) and Epigenetics and DNA Methylation (2 papers). Matti Davis collaborates with scholars based in United States, Australia and Israel. Matti Davis's co-authors include Yinon Ben‐Neriah, Jens Andersen, Matthias Mann, Avraham Yaron, Ada Hatzubai, Frank Mercurio, Sharon Amit, Anthony M. Manning, Iris Lavon and Khanhky Phamluong and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Matti Davis

8 papers receiving 931 citations

Hit Papers

Identification of the receptor component of the IκBα–ubiq... 1998 2026 2007 2016 1998 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matti Davis United States 7 736 264 237 199 156 8 949
Lam Leduy Canada 20 699 0.9× 233 0.9× 209 0.9× 123 0.6× 154 1.0× 29 1.0k
Eva Migon Canada 9 782 1.1× 175 0.7× 207 0.9× 263 1.3× 103 0.7× 9 1.0k
Cynthia L. Innes United States 16 585 0.8× 192 0.7× 255 1.1× 157 0.8× 74 0.5× 30 815
Nicola Manfrini Italy 18 905 1.2× 354 1.3× 156 0.7× 127 0.6× 59 0.4× 32 1.1k
Tiffany A. Melhuish United States 17 1.1k 1.5× 144 0.5× 261 1.1× 94 0.5× 207 1.3× 25 1.3k
Andreas Kloetgen United States 18 1.2k 1.6× 314 1.2× 164 0.7× 207 1.0× 70 0.4× 30 1.5k
Xicheng Mao United States 12 660 0.9× 299 1.1× 197 0.8× 238 1.2× 53 0.3× 19 979
Anna E. Burrows United States 5 649 0.9× 146 0.6× 155 0.7× 106 0.5× 85 0.5× 5 869
Shuhei Kotoshiba Japan 9 755 1.0× 130 0.5× 423 1.8× 125 0.6× 77 0.5× 11 930
Samantha G. Pattenden United States 16 1.2k 1.6× 112 0.4× 182 0.8× 161 0.8× 91 0.6× 25 1.4k

Countries citing papers authored by Matti Davis

Since Specialization
Citations

This map shows the geographic impact of Matti Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matti Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matti Davis more than expected).

Fields of papers citing papers by Matti Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matti Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matti Davis. The network helps show where Matti Davis may publish in the future.

Co-authorship network of co-authors of Matti Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Matti Davis. A scholar is included among the top collaborators of Matti Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matti Davis. Matti Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Ferrarotto, Renata, Oz Solomon, Rami Rauch, et al.. (2022). AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death and Disease. 13(8). 678–678. 32 indexed citations
2.
Rauch, Rami, Oz Solomon, Bill Kramer, et al.. (2019). Abstract 4885: AL101 mediated tumor inhibition in Notch mutated ACC PDX models. Cancer Research. 79(13_Supplement). 4885–4885. 3 indexed citations
3.
Solomon, Oz, Ido Sloma, Rami Rauch, et al.. (2019). AL101 mediated tumor inhibition in notch-altered TNBC PDX models.. Journal of Clinical Oncology. 37(15_suppl). 1064–1064. 16 indexed citations
4.
El-Khoueiry, Anthony B., Jayesh Desai, Swaminathan P. Iyer, et al.. (2018). A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2515–2515. 20 indexed citations
5.
Kanarek, Naama, E. Philip Horwitz, Gady Cojocaru, et al.. (2010). Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCFβ-TrCP by single substrate depletion. Genes & Development. 24(5). 470–477. 36 indexed citations
6.
Endoh‐Yamagami, Setsu, Marie Evangelista, Xiaohui Wen, et al.. (2009). The Mammalian Cos2 Homolog Kif7 Plays an Essential Role in Modulating Hh Signal Transduction during Development. Current Biology. 19(15). 1320–1326. 186 indexed citations
7.
Davis, Matti, Ada Hatzubai, Jens Andersen, et al.. (2002). Pseudosubstrate regulation of the SCF β-TrCP ubiquitin ligase by hnRNP-U. Genes & Development. 16(4). 439–451. 99 indexed citations
8.
Yaron, Avraham, Ada Hatzubai, Matti Davis, et al.. (1998). Identification of the receptor component of the IκBα–ubiquitin ligase. Nature. 396(6711). 590–594. 557 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026